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Lyme disease was recognized as a separate entity because of close geographic clusterilng of
affected children in Lyme, Connecticut, with what was thouglht to be juveniile rheumatoid ar-
thritis. It then became apparent that Lyme disease is a complex, multisystem disorder. The
illness usually begins in summer with erythema chroniicum migrans and associated symptoms
(stage 1). Weeks to montlhs later, some patients develop neurologic or cardiac abnormalities
(stage 2), and weeks to years later, many patients develop intermittenit attacks ofarthritis (stage
3), wlhichl may become chroniic, witlh erosion of cartilage and bone. Patients with severe anid
prolonged illness have an increased frequency ofthe B-cell alloantigeni, DR2. For patients with
early Lyme disease, tetracycline appears to be the most effective drug, theni penicillini, anid
finally erythromycin. High-dose intravenous penicillin is effective for the later stages of the
disease.
RECOGNITION OF THE DISEASE
We first learned about what was to become Lyme disease in October 1975 from
two mothers who reported to the Connecticut State Health Department that a
number of children who lived close together in Lyme, Connecticut, were thought to
havejuvenile rheumatoid arthritis (JRA) [1]. To investigate these reports, physicians
at the Health Department and the Yale University Rheumatology Section organized
a surveillance system through contacts with the mothers, area physicians, school
nurses, and local health officers in the three contiguous communities of Old Lyme,
Lyme, and East Haddam (total population, 12,000). In those communities, we at-
tempted to identify all children with inflammatory joint disease and invited them to
participate in a study at the Yale University School of Medicine where a history,
physical examination, and blood tests were done in an effort to determine the cause
of their arthritis.
We found 39 such children. All ofthem had an apparently similar type ofarthritis
characterized by briefbut recurrent attacks ofasymmetric swelling and pain in a few
large joints, especially the knee, over a period of years. Twelve adults, who were
either parents or neighbors ofaffected children, were found to have a similar type of
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All riglhts of reproductioni in aniy formn reserved.arthritis. Although individual attacks of arthritis were often shorter than those
usually seen in juvenile arthritis, it was difficult to separate the illness in Lyme
residents from that entity on the basis of joint involvement alone.
However, the epidemiologic analysis of affected residents was striking. The
overall prevalence rate of the disease was 4.3 per 1,000 residents; among children, it
was 12.2 per 1,000, a frequency at least 100 times greater than that of JRA [2]. Even
within these communities, close geographic clustering ofcases was observed. Halfof
the affected Lyme residents lived in heavily wooded areas on two adjoining country
roads, as did half of those affected in East Haddam. One in ten children living on
those four roads had the illness. In addition, clustering within families was ob-
served; six families had more than one affected member. The onset ofthe arthritis in
the 51 patients occurred during a four-year period from July 1972 through May 1976
(the cutoff time for the initial study); the majority (55 percent) noted the onset in
summer or early fall. In families with more than one affected member, those af-
fected usually had the onset of symptoms in different years. These epidemiologic
features seemed most compatible with an arthropod-transmitted illness.
Moreover, during a median of four weeks before the onset ofarthritis, 13 patients
(25 percent) noted an erythematous papule, thought to be an insect bite, that
developed into an expanding, red annular lesion. Only two of the 159 family
members ofpatients had such a lesion but did not develop arthritis (p <0.0000001).
The lesion sounded most compatible with erythema chronicum migrans (ECM), de-
scribed in Europe in 1909 [3]. There the lesion was associated with the bite ofIxodes
ricinus ticks [4] and with subsequent neurologic abnormalities [5,6] but not with ar-
thritis. Cultures and serologic tests in our patients did not suggest infection with ar-
boviruses or any other agents known to cause arthritis. Thus, we thought that the ill-
ness in Lyme residents was a previously unrecognized clincial entity and called it
"Lyme arthritis."
CLINICAL PICTURE
During the following summer of 1976, we identified, for the first time, patients
with the skin lesion, confirmed its similarity to ECM in Europe, and followed the
patients prospectively [7]. Many ofthem subsequently developed arthritis, but some
also acquired neurologic or cardiac abnormalities [8,9]. Thus, Lyme arthritis
became recognized as a complex, multisystem disorder, and the name was changed
to Lyme disease.
During the seven summers of 1976 through 1982, 314 patients with ECM were
studied prospectively at Yale [10]. Their ages ranged from 2 to 88 years (median, 28
years), and the sex ratio was nearly one to one. Onset ofthe illness was generally be-
tween May 1 and November 30; the majority ofonsets were in June or July [10]. The
following description of the illness is based primarily on the study ofthese patients.
Early Manifestations
Erythema chronicum migrans, the best clinical marker for Lyme disease, usually
begins as a red macule or papule [7,10]. Approximately 30 percent of the patients
remember a tick bite at the site ofthe lesion within 3 to 32 days before it forms there.
As the area of redness around the center expands, most lesions continue to have
bright red outer borders and partial central clearing (PLATE i). However, in some pa-
tients, ECM is less characteristic. The centers ofearly lesions sometimes become in-
tensely erythematous and indurated, as in streptococcal cellulitis; or the center
becomes vesicular and necrotic, as in tularemia. In some instances, migrating lesions
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remain an even intense red, several red rings are found within the outside one, or the
central area turns blue before it clears. Although the lesion can be located anywhere,
the thigh, groin, and axilla are particularly common sites. The lesion is hot to touch,
but often not painful. Histologically, the center of ECM shows dermal and epider-
mal changes, but only dermal changes in the periphery (Fig. 1), findings suggestive
of an arthropod bite.
In some patients, the disease remains localized to a single skin lesion accompanied
by minor constitutional symptoms-malaise and fatigue, headache, fever and chills,
and regional lymphadenopathy. The illness in these patients seems very similar to
ECM as described in Europe [3,4]. However, unlike the European experience, the
disease here often seems to disseminate [10]. Within several days after onset of the
initial skin lesion (ECM), many patients develop multiple annular secondary lesions
(PLATE II). Although their appearance is similar to initial lesions, they are generally
smaller, migrate less, and lack indurated centers; they are not associated with
previous tick bites. Patients with secondary lesions may be thought to have erythema
multiforme; however, in Lyme disease we have not seen blistering, mucosal lesions,
or involvement of the palms and soles. During this period, some patients develop
other dermatologic findings including malar rash, conjunctivitis, urticaria, or small
evanescent red blotches and circles.
Patients with disseminated disease sometimes have evidence of meningeal irrita-
tion, mild encephalopathy, migratory musculoskeletal pain, hepatitis, generalized
lymphadenopathy or splenomegaly, sore throat, non-productive cough, or testicular
swelling [10]. Except for lethargy and fatigue, which are often constant and may be
incapacitating, the early signs and symptoms are typically intermittent and chang-
ing. For example, a patient might experience predominantly headache and stiff neck
for several days. After a few days of improvement, musculoskeletal pain might
begin.
During this stage, the commonest non-specific laboratory abnormalities are a high
erythrocyte sedimentation rate (53 percent ofpatients), an elevated total serum IgM
level (33 percent), or an increased serum glutamic oxaloacetic transaminase (SGOT)
level (19 percent) [10]. The latter finding supports the clinical impression that mild
hepatitis may be a feature of early Lyme disease. A few patients have microscopic
hematuria, sometimes with mild proteinuria (dipstick), which has been the only
evidence of renal involvement. Regardless of treatment, the signs and symptoms of
FIG. 1. Histology of an initial skin lesion. Left: There is an infiltrationi of mononouclear cells
throughout all layers of the dermis. Right: At higher power, the cellular inifiltrate is seeni to colnsist
primarily of lymphocytes, histocytes, and a few plasma and mast cells.
455stage one usually fade within three to four weeks (range, 1 day to 14 months).
However, the dermatologic manifestations of the illness sometimes recur.
Later Manifestations
Nervous System Symptoms suggestive of meningeal irritation sometimes occur
at the beginning ofthe illness when ECM is present [10]. Such individuals often have
episodic attacks of excruciating headache and neck pain, stiffness, or pressure
typically lasting hours. During the first one or two weeks of illness, such symptoms
are not associated with a spinal fluid pleocytosis or objective neurologic deficit.
However, after several weeks to months, about 15 percent ofpatients develop frank
neurologic abnormalities. The usual triad of symptoms consists of meningitis, cra-
nial neuropathy (particularly Bell's palsy), and peripheral radiculoneuropathy.
However, any of these manifestations may occur alone [8]. In untreated patients,
neurologic abnormalities typically last for months but usually resolve completely.
Heart Within several weeks after the onset ofillness, about 8 percent ofpatients
develop cardiac involvement [9]. The commonest abnormality is fluctuating degrees
ofatrioventricular block (first degree, Wenckebach, or complete heart block). Some
patients have evidence of more diffuse cardiac involvement including elec-
trocardiographic changes compatible with acute myopericarditis, radionuclide
evidence of mild left ventricular dysfunction or, rarely, cardiomegaly. The duration
of cardiac involvement is usually brief (three days to six weeks) and rarely recurs.
The clinical picture in these patients has similarities to acute rheumatic fever, but in
Lyme disease, complete heart block may be more common, myopericardial involve-
ment tends to be milder, and valves seem not to be affected.
Joints Within a few weeks to two years after the onset of illness, about 60 per-
cent of patients develop arthritis [7,11,12]. Ifjoint involvement occurs early in the
illness, the typical pattern is one of migratory musculoskeletal pain in joints, ten-
dons, bursae, muscle, or bone, often withoutjoint swelling. The pain tends to affect
only one or two sites at a time and usually lasts a few hours to several days in agiven
location. Frank arthritis with marked joint swelling usually does not begin until
months after the onset ofthe illness. At that time, patients often experience intermit-
tent attacks ofjoint swelling and pain, primarily in large joints, especially the knee,
usually one or two joints at a time. Affected knees are commonly much more
swollen than painful, often hot, rarely red; Baker's cysts sometimes form and rup-
ture early. However, both large and small joints may be affected and a few patients
have had symmetrical polyarthritis, as in rheumatoid arthritis. Attacks of arthritis,
which generally last from a few weeks to months, typically recur for several years.
Late in the illness, fatigue is common with active joint involvement, but fever or
other systemic symptoms are unusual. Joint fluid white cell counts vary from 500 to
110,000 cells/mm3 with mostly polymorphonuclear leukocytes [7]. Total protein
ranges from 3 to 8 g/dl. C3 and C4 levels are generally greater than one-third and
glucose levels usually greater than two-thirds of that of serum.
In about 10 percent ofpatients with arthritis, involvement in largejoints becomes
chronic, with erosion of cartilage and bone [11,12]. Synovial biopsies show surface
deposits of fibrin, villous hypertrophy, vascular proliferation, and a heavy infiltra-
tion of mononuclear cells, including plasma cells presumably capable of producing
antibody locally (Fig. 2) [7,11,12]. In one patient with chronic Lyme arthritis,
synovium grown in tissue culture produced large amounts of collagenase and pros-
taglandin E2 [12]. Thus, in Lyme disease, the joint fluid cell counts, the immune
reactants (except for rheumatoid factor), the synovial histology, the amounts of
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FIG. 2. Histology ofaffected synovium. Left: Individual polypoid stalks show central edema, con-
gestion, vascular proliferation, and a heavy infiltration of mononuclear cells. Right: At higlher
power, the cellular infiltrate is shown to consist primarily of small lymphocytes and plasma cells.
synovial enzymes released, and the resulting destruction of cartilage and bone may
be similar to that in rheumtoid arthritis.
Variations in Clinical Manifestations
We have come to think of Lyme disease as an illness that occurs in stages, with
remissions and exacerbations and different clinical manifestations at each stage
(Table 1). The disorder usually begins with ECM and associated symptoms (stage 1).
Weeks to months later, some patients develop neurologic or cardiac abnormalities
(stage 2), and weeks to years later, many patients develop arthritis (stage 3).
However, it should be emphasized that marked variation is possible in the clinical
expression of the disease. Even without treatment, some patients have very mild
disease (e.g., ECM alone with no other manifestations). At the opposite end of the
spectrum, an occasional patient will have severe involvement of skin, nerves, heart,
and joints at the same time. Incomplete disease pictures are also possible. Some pa-
tients lack ECM but have other non-specific symptoms associated with stage one.
These patients are often thought to have viral infections. In other patients, stage one
is asymptomatic and the presenting signs of the disease are neurologic or joint in-
volvement. These patients may be diagnosed as having aseptic meningitis, rheuma-
toid arthritis, juvenile arthritis, or Reiter's syndrome.
The development of severe and prolonged illness is associated with a particular
genetic susceptibility [11,13]. In a study of45 patients at the two ends of the clinical
spectrum of Lyme disease, those with severe and prolonged illness (ECM followed
by meningitis or chronic arthritis) had an increased frequency of the B-cell alloan-
tigen, DR2 (67 percent of patients) compared to 36 percent of those with mild and
brief illness (ECM alone) (odds ratio = 3.4, p<0.05) or to 25 percent of those in a
TABLE 1
Stages of Lyme Diseasea
Stage Manifestation
1 ECM and associated symptoms
2 Neurologic or cardiac abnormalities
3 Arthritis
aThe stages may overlap or occur alone.
A P-_normal population (odds ratio = 6, p<0.0001). Thus, Lyme disease seems to fit
within a pathogenetic framework thought to be important in several rheumatic
diseases; namely, in genetically susceptible individuals, certain infectious agents may
be associated with a characteristic immune response that leads to arthritis.
TREATMENT
We initially suspected that Lyme disease was a viral illness. However, in Europe,
where associated arthritis was unknown, ECM was said to respond to antibiotic
therapy [14,151, and case reports supporting that conclusion had also appeared in
the United States [16,17]. Therefore, during the 1977 and 1979 summers, we gave
antibiotics to patients with active ECM and compared the results with those in un-
treated patients from the summers of 1976 and 1978. Based on these observations,
we reported that penicillin, given early in the illness, shortened the duration ofECM
and appeared to prevent or attenuate subsequent arthritis [18].
To further clarify these findings, during 1980 and 1981, 108 patients with early
Lyme disease were assigned treatment randomly with phenoxymethyl penicillin,
erythromycin, or tetracycline, in each instance 250 mg four times a day for ten days
[19]. The patients in each group had similar age and sex distributions, and the mean
duration in each from the onset of illness to the beginning of antibiotic therapy was
nine to ten days. Fourteen percent of patients, generally those with more severe
disease, had an intensification of symptoms during the first 24 hours after the start
of therapy. This Jarisch-Herxheimer-like reaction occurred more often with penicil-
lin and tetracycline than with erythromycin, presumably because of faster killing of
larger numbers of organisms.
ECM and its associated symptoms resolved significantly faster in penicillin- or
tetracycline-treated patients than in those given erythromycin (mean duration, 5.4
and 5.7 versus 9.2 days, F = 3.38, p < 0.05) [19]. In addition, fewer patients given
penicillin (5 percent) or tetracycline (8 percent) than those treated with erythromycin
(17 percent) required retreatment (ten more days of antibiotics) because of per-
sistence of symptoms or immediate relapse. More important, none ofthe 39 patients
given tetracycline developed major late complications (myocarditis, meningo-
encephalitis, or recurrent attacks of arthritis) compared with 3 of 40 penicillin-
treated patients (8 percent) and 4 of 29 given erythromycin (14 percent) (p = 0.07).
In 1982, all 49 adult patients were given tetracycline; again, none ofthem developed
major complications. Thus, for adults early in the illness, tetracycline, 250 mg four
times a day, seems to be the drug of choice, followed by phenoxymethyl penicillin,
500 mg four times a day, and erythromycin, 250 mg four times a day, in each in-
stance for at least ten days or for up to 20 days if symptoms persist or recur [19]. In
children, we recommend phenoxymethyl penicillin 50 mg/kg/d (not less than 1 g/d
or more than 2 g/d) in divided doses for the same duration or, in cases ofpenicillin
allergy, erythromycin, 30 mg/kg/d, in divided doses for 15 or 20 days.
Regardless of the antibiotic agent given, nearly half of patients still experienced
minor late complications-recurrent episodes of headache or pain in joints, ten-
dons, bursae, or muscles, often accompanied by lethargy [19]. Their physical ex-
aminations were usually normal. Symptoms were often reminiscent of those ex-
perienced at the beginning of the illness, but were generally briefer and less severe.
They correlated significantly with the initial severity of the illness. In a given attack,
pain usually occurred in one or two sites and lasted from hours to days. With fre-
quent attacks, the pain was often migratory. Such attacks sometimes recurred for
several years. The pathogenesis of these symptoms is unknown. A severely depleted
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number oflive spirochetes may continue to produce these less serious but sometimes
debilitating symptoms. Alternately, they may not require the persistence of an intact
spirochete.
Can the later manifestations of Lyme disease be treated with antibiotic therapy?
In 1981 and 1982, we treated 12 patients with intravenous penicillin, 20 million U a
day in divided doses, for neurologic abnormalities of Lyme disease [20]. Headache,
stiff neck, and radicular pain usually began to subside by the second day of therapy
and were often gone by seven to ten days. Compared to 15 previous patients treated
with prednisone alone, the duration of meningitic symptoms was significalntly
shorter in those given penicillin (mean duration, one versus 29 weeks,p <0.0000001).
However, in both groups a mean of seven to eight weeks was required for complete
recovery ofmotor deficits. Thus, we concluded that high-dose intravenous penicillin
is effective therapy for neurologic abnormalities of Lyme disease. However, similar
to the experience with oral antibiotics for ECM, 3 of the 12 patients continued to
have frequent arthralgias, musculoskeletal pain, and fatigue despite penicillin
therapy.
Cardiac involvement should also be treated with antibiotics, either oral
tetracycline or intravenous penicillin [unpublished observations]. In addition, our
practice is to include aspirin therapy, generally 3.6 g/d, or prednisone, 40 to 60
mg/d, if the patient has complete heart block and cardiomegaly [9].
Established Lyme arthritis can also be treated successfully with high-dose intra-
venous penicillin [21]. In a double-blind, placebo-controlled trial, seven of 16 pa-
tients whoreceived intramuscular benzathinepenicillin remained well afterward, but
all 20 patients given saline continued to have attacks of arthritis (p = 0.001). In a
subsequent study, 13 of 20 patients given penicillin G, 20 million U a day intra-
venously for ten days, have remained well, including both patients who were Bicillin
faihires.
REFERENCES
1. Steere AC, Malawista SE, Snydman DR, Shope RE, Andiiman WA, Ross MR, Steele FM: Lyme ar-
thritis: An epidemic of oligoartricular arthritis in children and adults in three Conniecticut com-
munities. Arthritis Rheum 20:7-17, 1977
2. Baum J: Epidemiology ofjuvenile rheumatoid arthritis (JRA). Arthritis Rheum (suppl) 20:158-160,
1977
3. Afzelius A: Report to Verhandlungen der dermatologischenl Gesellschaft zu Stockholm on December
16, 1909. Arch Dermatol Syph 101:405-406, 1910
4. Thone AW: Ixodes ricinus and Erythema chronicum migrans (Afzelius). Dermatologica 136:57-60,
1968
5. Garin-Bujadoux C: Paralysie par les Tiques. J Med Lyon 71:765-767, 1922
6. Horstrup P, Ackermann R: Durch zecken ubertragene Meningopolynleuritis (Garin-Bujadoux, Banni-
warth). Fortschr Neurol Psychiatr 41:583-606, 1973
7. Steere AC, Malawista SE, Hardin JA, Ruddy S, Askenase PW, Andimnal WA: Erythema chronlicum
migrans and Lyme arthritis: The enlarging clinical spectrum. Anni Interni Med 86:685-698, 1977
8. Reik L, Steere AC, Bartenhagen NH, Shope RE, Malawista SE: Neurologic abnormalities of Lymne
disease. Medicine 58:281-294, 1979
9. Steere AC, Batsford WP, Weinberg M, Alexander J, Berger HJ, Wolfson S, Malawista SE: Lyme
carditis: Cardiac abnormalities of Lyme disease. Ann Interni Med 93:8-16, 1980
10. Steere AC, Bartenhagen NH, Craft JE, Hutchinson GJ, Newman JH, Rahni DW, Sigal LH, Spieler
PN, Stenn KS, Malawista SE: The early clinical manifestations of Lyme disease. Ann Internl Med
99:76-82, 1983
11. Steere AC, Gibofsky A, Patarroyo ME, Winchester RJ, Hardin JA, Malawista SE: Chroniic Lyme
arthritis: Clinical and immunogenetic differentiation from rheumatoid arthritis. Ann lnternl Med
90:286-291, 1979
12. Steere AC, Brinkerhoff CE, Miller DJ, Drinker H, Harris ED Jr, Malawista SE: Elevated levels of460 STEERE ET AL.
collagenase and prostagladin E2 from synovium associated with erosion of cartilage anid bonie in a
patient with clhronic Lyme arthritis. Arthritis Rheum 238:591-599, 1980
13. Steere AC, Gibofsky A, Hardin JA, Winchester RJ, Malawista SE: Lyme artlhritis: limmunologic anid
immunogenetic markers. Arthritis Rheum 22:662, 1979 (abstract)
14. Hollstrom E: Successful treatment of erythema migrans Afzelius. Acta Derm Veniereol (Stockh)
31:235-243, 1951
15. Hollstrom E: Penicillin treatment of erythema chroniicum migrans Afzelius. Acta Derin Venereol
(Stockh) 38:285-289, 1958
16. Scrimenti RJ: Erythema chronicum migrans. Arch Dermatol 102:104-105, 1970
17. Mast WE, Burrows WM Jr: Erythema chronicum migrans in the United States, JAMA 236:859-860,
1976
18. Steere AC, Malawista SE, Newman JH, Spieler PN, Bartenhlageni NH: Antibiotic tlherapy in Lyine
disease. Ann Intern Med 93:1-8, 1980
19. Steere AC, Hutchinson GJ, Rahin DW, Sigal LH, Craft JE, DeSannia ET, Malawista SE: Treatmenit
of the early manifestations of Lyme disease. Anni Iintern Med 99:22-26, 1983
20. Steere AC, Pachner AR, Malawista SE: Neurologic abniormalities of Lyme disease: Successful treat-
ment with high-dose intravenous penicillin. Ann Intern Med 99:767-772; 1983
21. Steere AC, Green J, Hutchinson GJ, Rahn DW, Schoen R, Sigal LH, Malawista SE: Curing Lyme
arthritis: Successful antibiotic therapy of established joint involvement (abstract). Arthritis Rheum
27:S26, 1984THE CLINICAL SPECTRUM AND TREATMENT OF LYME DISEASE
PLATE I. Erythema chroni-
cummigrans. Aten-day-old
lesion has gradually ex-
panded to 10 cm and is be-
ginning to have a brighter
red border.
PLATE I. Multipleannular
secondary lesions. Four
days after onset of ECM,
small secondary lesions
have appeared on the trunk
and legs.
461